Drug Profile
Research programme: anti-tau antibodies - Voyager Therapeutics
Alternative Names: Vectorized tau antibodies - Voyager TherapeuticsLatest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Voyager Therapeutics
- Class Antidementias; Gene therapies; Monoclonal antibodies
- Mechanism of Action Gene transference; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Frontotemporal dementia; Progressive supranuclear palsy
Most Recent Events
- 04 Jan 2024 Preclinical development in Alzheimer's-disease is still ongoing in USA (IV)
- 09 May 2023 Voyager Therapeutics announces intention to submit IND application to regulatory body for Alzheimer's disease in 2024
- 28 Mar 2023 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Voyager Therapeutics